Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 275 posts found.

GSK enters agreement for license for JNJ-3089 for development of bepirovirsen

November 2, 2023
Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B

GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen Pharmaceuticals, a Johnson & Johnson …

News

Janssen and Sanofi enter agreement for potential vaccine programme

October 5, 2023
Business Services Immunology, Janssen, Sanofi, e coli, vaccines

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with Sanofi for Janssen’s extraintestinal pathogenic …

News
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

Janssen submits sNDA to FDA for full approval of Balversa

August 29, 2023
Research and Development Balversa, FDA, Janssen, Oncology

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental New Drug Application (sNDA) to …

News

FDA approved Janssen’s Akeega for prostate cancer treatment

August 14, 2023
Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …

News
pawel-czerwinski-2y8ol_obs1i-unsplash_2

FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023
Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …

News

Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment

July 10, 2023
Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix

Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …

News
janssen_latest_logo_on_sign_closer

Janssen CLL treatment combination sees success in trials

June 14, 2021
Sales and Marketing CLL, Janssen

Janssen has announced positive data from its Phase III GLOW study, with the combination of imbruvica (ibrutinib) plus venetoclax (I+V) …

News

NICE recommends Janssen’s active psoriatic arthritis drug

May 28, 2021
Medical Communications Janssen, NICE, UK, arthritis

NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new option for treating active psoriatic …

News
janssen_latest_logo_on_sign_closer

Janssen sees promising PRO data for prostate cancer therapy

May 27, 2021
Janssen, prostate cancer

Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase III TITAN study in patients …

News
janssen_latest_logo_on_sign

Janssen submits MAA to EMA for novel CAR-T cell therapy

May 5, 2021
Research and Development EMA, EU, Janssen, multiple myeloma

Janssen have submitted a Marketing Authorisation Application (MAA) to the EMA seeking approval of cilta-cel, an investigational B cell maturation …

News

J&J vaccine halted in US due to blood clots

April 14, 2021
Research and Development CDC, COVID-19 vaccine, FDA, Janssen, Johnson & Johnson, pharma, pharma news

The CDC and FDA have recommended a pause in the use of the Johnson & Johnson COVID-19 vaccine in the …

News
Janssen sign

Janssen agrees $780 million deal for authorisation of Cidara flu treatment

April 6, 2021
Manufacturing and Production Janssen, cidara, influenza

Janssen has struck a deal worth up to $780 million with Cidara Therapeutics for exclusive worldwide rights to Cidara’s CD388 …

News

J & J to ship up to 400 million vaccines to Africa

March 30, 2021
Manufacturing and Production COVAX, COVID-19, COVID-19 vaccine, Janssen, Johnson & Johnson

Johnson & Johnson has reached an agreement to ship as many as 400 million doses of their COVID-19 vaccine to …

News

Janssen’s multiple sclerosis treatment recommended by EMA

March 29, 2021
Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis

Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …

News
Janssen sign

Johnson & Johnson’s arthritis drug shows promising results in Phase III trial

March 16, 2021
Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024